Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, effectively suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models. The findings, published in the Journal of Oncology Research and Therapy, provide a scientific foundation for the company's planned Phase 1/2 clinical trial in TNBC, which is already cleared under an active Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
The study reveals that Telomir-Zn works by selectively modulating intracellular iron and copper levels. By depleting intracellular iron, the compound inhibits histone demethylases, enzymes that play a role in gene expression. This mechanism selectively kills iron-dependent TNBC cells while sparing normal cells, even at concentrations more than 50-fold higher than those effective against cancer cells. Additionally, Telomir-Zn reactivated tumor-suppressor genes in a prostate cancer model, further highlighting its epigenetic regulatory potential.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, in BT-549 xenografts, combining Telomir-Zn with paclitaxel produced significantly greater tumor reduction than either treatment alone. However, MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity that may guide patient selection in future trials.
These results are particularly significant given the aggressive nature of triple-negative breast cancer, which lacks targeted therapies and has a poor prognosis. The ability of Telomir-Zn to inhibit metastasis and enhance the efficacy of standard chemotherapy like paclitaxel suggests it could become a valuable addition to the treatment arsenal. The company plans to advance Telomir-Zn into a Phase 1/2 clinical trial in patients with advanced or metastatic TNBC, leveraging the IND clearance already granted by the FDA.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic pathways involved in cancer. Telomir-Zn, its lead program, is designed to modulate intracellular metal homeostasis and epigenetic regulation, offering a novel approach to cancer treatment. The positive preclinical data not only validate the scientific rationale but also position the company to move forward with clinical development.
The publication of these findings in a peer-reviewed journal adds credibility to the data and underscores the potential of Telomir-Zn as a targeted therapy. As the company progresses toward clinical trials, the oncology community will be watching closely to see if these promising preclinical results translate into patient benefit. For more information on the full press release, visit https://ibn.fm/mv3hn.
